ChemicalBook > CAS DataBase List > EFALIZUMABUM

EFALIZUMABUM

Product Name
EFALIZUMABUM
CAS No.
214745-43-4
Chemical Name
EFALIZUMABUM
Synonyms
EFALIZUMABUM;Hu1124|||HU 1124;Efalizumab (anti-ITGAL);Research Grade Efalizumab;Research Grade Efalizumab(DHD41001)
CBNumber
CB72631887
Formula Weight
0
MOL File
Mol file
More
Less

EFALIZUMABUM Property

form 
Liquid
color 
Colorless to light yellow
More
Less

Safety

Hazardous Substances Data
214745-43-4(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

American Custom Chemicals Corporation
Product number
ATB0023424
Product name
EFALIZUMAB
Purity
95.00%
Packaging
5MG
Price
$497.29
Updated
2021/12/16
More
Less

EFALIZUMABUM Chemical Properties,Usage,Production

Description

Efalizumab, a humanized monoclonal antibody marketed for the treatment of psoriasis, is a full-length IgG1 antibody developed through a murine anti-human CD11a mAb. It is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. Psoriasis is a disease mediated through inflammatory cells (primarily T-cells expressing CD4 or CD8 markers) and keratinocytes. CD11a is the alpha-chain LFA-1 (leukocyte function associate antigen; integrin family). It is expressed on the surface of Tlymphocytes and it binds to the intercellular cell adhesion molecules (ICAM-1, -2 and -3) on endothelial cells, monocytes, keratinocytes, fibroblasts, and activated lymphocytes. By blocking LFA-1 binding the ability of T cells to adhere, migrate and be activated is blunted. Studies in chimpanzee and murine animal models demonstrated that efalizumab down regulates the expression of LFA-1 on lymphocytes, prevents contact dermatitis to 2,4-dinitrofluorobenzene, increases skin and heart transplant survival. In the collagen-induced arthritis model it delays onset and decreases the severity of the arthritic condition. In a study of 498 patients, efalizumab treatment of 1 or 2 mg/kg/wk for 12 weeks provided, respectively, a 39 or 27% Psoriasis Area and Severity Score (PASI) improvement of ≥75%. By comparison, placebo provided a 2% improvement. It was further demonstrated that a second 12-week course could provide additional improvement. As dose increases, clearance decreases (dose 0.1 mg/kg: 322 ml/day/kg; dose 10 mg/kg: 6.6 mL/day/kg) with data suggesting saturation of clearance above 10 mg/mL. A pharmacokinetic model positively correlates number of circulating cells expressing CD11a with relative clearance. This blockade decreases the CD11a expressed on circulating lymphocytes to about 25% of their baseline levels in patients with plaque psoriasis. Efalizumab is formulated as a once-weekly subcutaneous injectable, dosed at 0.7 to 1 mg/kg/week. Although mild adverse events were noted such as headache, pain chills, nausea, and fever, these events generally decreased after one or two doses. The overall rate of infections was only 3% higher than the placebo-arm and no depletion of T-cells was noted.

Originator

XOMA (US)

Uses

Treatment of transplant rejections; antipsoriatic (immunomodulator monoclonal antibody which decreases the activation, migration, and adhesion of T-cells). hu1124; anti-CD11a.

brand name

Raptiva

in vivo

Efalizumab shows side effects include bacterial sepsis, viral meningitis, invasive fungal disease and progressive multifocal leukoencephalopathy (PML), a brain infection caused by reactivation of latent JC virus infection[2].

EFALIZUMABUM Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

EFALIZUMABUM Suppliers

Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Fax
QQ:422450190
Email
422450190@qq.com
Country
China
ProdList
10308
Advantage
58
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
71826
Advantage
60
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8000
Advantage
62
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
Country
China
ProdList
1566
Advantage
58
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Country
China
ProdList
24961
Advantage
58
Biolab Reagents
Tel
027-65279366 18108604356
Email
products@biolabreagent.com
Country
China
ProdList
9868
Advantage
58
Wuhan Jingkangen Biomedical Technology Co., Ltd
Tel
13720134139 086-15871494362 13720134139
Email
orders@jknbiochem.com
Country
China
ProdList
6762
Advantage
58
Shanghai Yifei Biotechnology Co. , Ltd.
Tel
021-65675885 18964387627
Email
customer_service@efebio.com
Country
China
ProdList
11973
Advantage
58
Shanghai Aladdin Biochemical Technology Co.,Ltd.
Tel
400-6206333 13167063860
Email
anhua.mao@aladdin-e.com
Country
China
ProdList
48457
Advantage
58
Changsha Fuzhen Biotechnology Co.,LTD
Tel
0731-13823398 15111215862
Email
313359644@qq.com
Country
China
ProdList
4161
Advantage
58

214745-43-4, EFALIZUMABUMRelated Search:


  • EFALIZUMABUM
  • Research Grade Efalizumab(DHD41001)
  • Efalizumab (anti-ITGAL)
  • Hu1124|||HU 1124
  • Research Grade Efalizumab
  • 214745-43-4